Truist Securities Reiterates Buy Rating on Tourmaline Bio (TRML)

September 11, 2024 7:03 AM EDT Send to a Friend
Truist Securities analyst Srikripa Devarakonda reiterated a Buy rating and $74.00 price target on Tourmaline Bio (NASDAQ: TRML).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login